The two most common chronic inflammatory skin diseases are atopic dermatitis (AD) and psoriasis. The underpinnings of the remarkable degree of clinical heterogeneity of AD and psoriasis are poorly understood and, as a consequence, disease onset and progression are unpredictable and the optimal type and time point for intervention are as yet unknown. The BIOMAP project is the first IMI (Innovative Medicines Initiative) project dedicated to investigating the causes and mechanisms of AD and psoriasis and to identify potential biomarkers responsible for the variation in disease outcome. The consortium includes 7 large pharmaceutical companies and 25 non-industry partners including academia. Since there is mounting evidence supporting an important role for microbial exposures and our microbiota as factors mediating immune polarization and AD and psoriasis pathogenesis, an entire work package is dedicated to the investigation of skin and gut microbiome linked to AD or psoriasis. The large collaborative BIOMAP project will enable the integration of patient cohorts, data and knowledge in unprecedented proportions. The project has a unique opportunity with a potential to bridge and fill the gaps between current problems and solutions. This review highlights the power and potential of the BIOMAP project in the investigation of microbe-host interplay in AD and psoriasis.
Bibliographical noteFunding Information:
The research has received funding from the FP7 (MAARS?Grant 261366) and IMI2 (BIOMAP?Grant 821511).
The research has received funding from the FP7 (MAARS—Grant 261366) and IMI2 (BIOMAP—Grant 821511).
Funding agencies have widely embraced collaborative funding models for research consortia such as the large‐scale Innovative Medicines Initiative (IMI). IMI is a public‐private partnership that aims to improve health by speeding up the development of innovative medicines, particularly in areas where there is an unmet medical and/or social need. IMI is the world's biggest public‐private partnership in the life sciences. The partnership includes the European Commission (EC) (representing the EU) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) (representing pharmaceutical industry partners), and is supported by these two parties. Industry partners contribute to the projects in a variety of ways, including bringing in‐kind consortium capacity and knowhow, while the EC matches the overall value of these contributions to fund activities provided by academia, small‐ to medium‐sized enterprises, and other non‐industry groups. Since 2006, the IMI has funded more than 120 projects with more than 1.5 billion € of EU funding focused on major diseases affecting European citizens. 178
© 2021 The Authors. Experimental Dermatology published by John Wiley & Sons Ltd.
- atopic dermatitis